AstraZeneca, Others Hit With Nexium Pay-For-Delay Suits
Three putative class actions filed Friday in Pennsylvania federal court accuse AstraZeneca PLC and several generic-drug makers of violating antitrust laws by entering agreements to delay entry of a generic version...To view the full article, register now.
Already a subscriber? Click here to view full article